USA flag logo/image

An Official Website of the United States Government

Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of…

Award Information

Agency:
Department of Defense
Branch:
Office for Chemical and Biological Defense
Award ID:
81825
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
C071-113-0151
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stratatech Corporation
505 S. Rosa Road, Suite 169 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of Vesicant Burns
Agency / Branch: DOD / CBD
Contract: W81XWH-07-C-0063
Award Amount: $749,790.00
 

Abstract:

Cutaneous wounds, such as those resulting from vesicant exposure and thermal injuries, provide an ideal environment for bacterial growth and the complications stemming from wound sepsis. The availability of ready-to-use, antimicrobial skin substitutes that are readily deployed in the field would provide immediate wound closure and reduce the incidence of infection in these wounds. To address these needs, Stratatech Corporation is developing a field-ready, tissue engineered antimicrobial therapeutic called EpiReadyDefenseT for treatment of vesicant, thermal and traumatic cutaneous injuries. This product is designed to contain elevated levels of naturally-occurring antimicrobial peptides in the context of a fully-stratified skin substitute that is ready to use and stable at ambient temperatures. During Phase II of the project, procedures will be developed to optimize Stratatech's existing antimicrobial skin substitute for ambient storage. Efforts will focus on preserving tissue architecture and strength, as well as maintaining the antimicrobial properties required in the final product. The antimicrobial properties of EpiReadyDefenseT will be determined in an established animal model of burn wound infection. Phase II studies will also include preclinical, in vivo wound healing studies that will be required to support ultimate clinical evaluation and approval of EpiReadyDefenseT tissue.

Principal Investigator:

Barry Steiglitz
Molecular Biology Scienti
6084412750
bsteiglitz@stratatechcorp.com

Business Contact:

Robert T. Barnard
Vice President and Treasu
6084412750
rbarnard@stratatechcorp.com
Small Business Information at Submission:

STRATATECH CORP.
505 S. Rosa Road, Suite 169 Madison, WI 53704

EIN/Tax ID: 392025242
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No